Industrial-Scale Microbiome Mining (ISMM) reveals low-abundance microbial small molecules that appear to coordinate multiple human appetite and energy-balance nodes within a single, orally oriented scaffold—raising satiety and energy expenditure (MC4R), suppressing hunger drive (GHSR antagonism), and dampening hedonic reinforcement (OPRM1/OPRD1), with HTR2C and C3aR as supportive nodes. New GLP-1 receptor (GLP-1R) docking completed after the first draft additionally suggests that the same scaffold can act as a moderate-affinity positive allosteric modulator at a novel TM3–4–5 interface on GLP-1R, adding meal-linked incretin support without converting the program into a classical GLP-1 agonist play. This unimolecular polypharmacology is intended to deliver durable weight control with comfortable fullness as the default experience; if exposure is higher or eating continues beyond satiety, an on-target aversive “do-not-eat-more” signal is anticipated and can be tuned by IR/ER exposure strategies. The program targets a high-value gap in metabolic health by pursuing an oral, adherent, and durable approach distinct from injectable peptide incretin therapies and high-potency orthosteric GLP-1 agonists while remaining anchored to validated human biology.